Bipolar Disorder Questions & Answers

1. Bowden C, Singh V. Long-term management of bipolar disorder. Available at http://www.medscape.com/viewprogram/2686.

2. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fifth Edition. Washington, DC: American Psychiatric Association; 2013.

3. 69. Management of Bipolar Disorder Working Group. VA/DoD clinical practice guideline for management of bipolar disorder in adults. Washington, DC: Department of Veterans Affairs, Department of Defense; 2010. Available at http://guideline.gov/content.aspx?id=16314. Accessed: May 15, 2012.

4. Zhang D, Cheng L, Qian Y, Alliey-Rodriguez N, Kelsoe JR, Greenwood T, et al. Singleton deletions throughout the genome increase risk of bipolar disorder. Mol Psychiatry. 2009 Apr. 14(4):376-80. [QxMD MEDLINE Link]. [Full Text].

5. Price AL, Marzani-Nissen GR. Bipolar disorders: a review. Am Fam Physician. 2012 Mar 1. 85(5):483-93. [QxMD MEDLINE Link].

6. Ketter TA. Diagnostic features, prevalence, and impact of bipolar disorder. J Clin Psychiatry. 2010 Jun. 71(6):e14. [QxMD MEDLINE Link].

7. Edvardsen J, Torgersen S, Røysamb E, Lygren S, Skre I, Onstad S, et al. Heritability of bipolar spectrum disorders. Unity or heterogeneity?. J Affect Disord. 2008 Mar. 106(3):229-40. [QxMD MEDLINE Link].

8. Berrettini WH, Ferraro TN, Goldin LR, Weeks DE, Detera-Wadleigh S, Nurnberger JI Jr, et al. Chromosome 18 DNA markers and manic-depressive illness: evidence for a susceptibility gene. Proc Natl Acad Sci U S A. 1994 Jun 21. 91(13):5918-21. [QxMD MEDLINE Link]. [Full Text].

9. Reich T, Clayton PJ, Winokur G. Family history studies: V. The genetics of mania. Am J Psychiatry. 1969 Apr. 125(10):1358-69. [QxMD MEDLINE Link].

10. Lin PI, McInnis MG, Potash JB, Willour VL, Mackinnon DF, Miao K, et al. Assessment of the effect of age at onset on linkage to bipolar disorder: evidence on chromosomes 18p and 21q. Am J Hum Genet. 2005 Oct. 77(4):545-55. [QxMD MEDLINE Link]. [Full Text].

11. McQuillin A, Bass NJ, Kalsi G, Lawrence J, Puri V, Choudhury K, et al. Fine mapping of a susceptibility locus for bipolar and genetically related unipolar affective disorders, to a region containing the C21ORF29 and TRPM2 genes on chromosome 21q22.3. Mol Psychiatry. 2006 Feb. 11(2):134-42. [QxMD MEDLINE Link].

12. Ekholm JM, Kieseppä T, Hiekkalinna T, Partonen T, Paunio T, Perola M, et al. Evidence of susceptibility loci on 4q32 and 16p12 for bipolar disorder. Hum Mol Genet. 2003 Aug 1. 12(15):1907-15. [QxMD MEDLINE Link].

13. Abou Jamra R, Fuerst R, Kaneva R, Orozco Diaz G, Rivas F, Mayoral F, et al. The first genomewide interaction and locus-heterogeneity linkage scan in bipolar affective disorder: strong evidence of epistatic effects between loci on chromosomes 2q and 6q. Am J Hum Genet. 2007 Nov. 81(5):974-86. [QxMD MEDLINE Link]. [Full Text].

14. Kelsoe JR, Spence MA, Loetscher E, Foguet M, Sadovnick AD, Remick RA, et al. A genome survey indicates a possible susceptibility locus for bipolar disorder on chromosome 22. Proc Natl Acad Sci U S A. 2001 Jan 16. 98(2):585-90. [QxMD MEDLINE Link]. [Full Text].

15. Kakiuchi C, Iwamoto K, Ishiwata M, Bundo M, Kasahara T, Kusumi I, et al. Impaired feedback regulation of XBP1 as a genetic risk factor for bipolar disorder. Nat Genet. 2003 Oct. 35(2):171-5. [QxMD MEDLINE Link].

16. Ferreira MA, O'Donovan MC, Meng YA, Jones IR, Ruderfer DM, Jones L, et al. Collaborative genome-wide association analysis supports a role for ANK3 and CACNA1C in bipolar disorder. Nat Genet. 2008 Sep. 40(9):1056-8. [QxMD MEDLINE Link]. [Full Text].

17. Large-scale genome-wide association analysis of bipolar disorder identifies a new susceptibility locus near ODZ4. Nat Genet. 2011 Sep 18. 43(10):977-83. [QxMD MEDLINE Link]. [Full Text].

18. Baum AE, Akula N, Cabanero M, Cardona I, Corona W, Klemens B, et al. A genome-wide association study implicates diacylglycerol kinase eta (DGKH) and several other genes in the etiology of bipolar disorder. Mol Psychiatry. 2008 Feb. 13(2):197-207. [QxMD MEDLINE Link]. [Full Text].

19. Genome-wide association study of 14,000 cases of seven common diseases and 3,000 shared controls. Nature. 2007 Jun 7. 447(7145):661-78. [QxMD MEDLINE Link]. [Full Text].

20. Sklar P, Smoller JW, Fan J, Ferreira MA, Perlis RH, Chambert K, et al. Whole-genome association study of bipolar disorder. Mol Psychiatry. 2008 Jun. 13(6):558-69. [QxMD MEDLINE Link]. [Full Text].

21. McQuillin A, Rizig M, Gurling HM. A microarray gene expression study of the molecular pharmacology of lithium carbonate on mouse brain mRNA to understand the neurobiology of mood stabilization and treatment of bipolar affective disorder. Pharmacogenet Genomics. 2007 Aug. 17(8):605-17. [QxMD MEDLINE Link].

22. National Institutes of Health.NIH News. Schizophrenia and bipolar disorder share genetic roots. Available at http://www.nih.gov/news/health/jul2009/nimh-01.htm. Accessed: August 26, 2009.

23. Identification of risk loci with shared effects on five major psychiatric disorders: a genome-wide analysis. Lancet. 2013 Apr 20. 381(9875):1371-9. [QxMD MEDLINE Link]. [Full Text].

24. Post RM, Speer AM, Hough CJ, Xing G. Neurobiology of bipolar illness: implications for future study and therapeutics. Ann Clin Psychiatry. 2003 Jun. 15(2):85-94. [QxMD MEDLINE Link].

25. Roybal K, Theobold D, Graham A, DiNieri JA, Russo SJ, Krishnan V, et al. Mania-like behavior induced by disruption of CLOCK. Proc Natl Acad Sci U S A. 2007 Apr 10. 104(15):6406-11. [QxMD MEDLINE Link]. [Full Text].

26. Coyle JT. What can a clock mutation in mice tell us about bipolar disorder?. Proc Natl Acad Sci U S A. 2007 Apr 10. 104(15):6097-8. [QxMD MEDLINE Link]. [Full Text].

27. Bearden CE, Freimer NB. Endophenotypes for psychiatric disorders: ready for primetime?. Trends Genet. 2006 Jun. 22(6):306-13. [QxMD MEDLINE Link].

28. American College of Neuropsychopharmacology. American College of Neuropsychopharmacology 2010 annual meeting abstracts. December 5-9, 2010; Miami Beach, Fla.

29. Potash JB, Toolan J, Steele J, Miller EB, Pearl J, Zandi PP, et al. The bipolar disorder phenome database: a resource for genetic studies. Am J Psychiatry. 2007 Aug. 164(8):1229-37. [QxMD MEDLINE Link].

30. Cichon S, Mühleisen TW, Degenhardt FA, Mattheisen M, Miró X, Strohmaier J, et al. Genome-wide association study identifies genetic variation in neurocan as a susceptibility factor for bipolar disorder. Am J Hum Genet. 2011 Mar 11. 88(3):372-81. [QxMD MEDLINE Link]. [Full Text].

31. Graae L, Karlsson R, Paddock S. Significant association of estrogen receptor binding site variation with bipolar disorder in females. PLoS One. 2012. 7(2):e32304. [QxMD MEDLINE Link]. [Full Text].

32. Grozeva D, Kirov G, Ivanov D, Jones IR, Jones L, Green EK, et al. Rare copy number variants: a point of rarity in genetic risk for bipolar disorder and schizophrenia. Arch Gen Psychiatry. 2010 Apr. 67(4):318-27. [QxMD MEDLINE Link].

33. Aston C, Jiang L, Sokolov BP. Transcriptional profiling reveals evidence for signaling and oligodendroglial abnormalities in the temporal cortex from patients with major depressive disorder. Mol Psychiatry. 2005 Mar. 10(3):309-22. [QxMD MEDLINE Link].

34. Davis KL, Haroutunian V. Global expression-profiling studies and oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003 Sep 6. 362(9386):758. [QxMD MEDLINE Link].

35. Prabakaran S, Swatton JE, Ryan MM, Huffaker SJ, Huang JT, Griffin JL, et al. Mitochondrial dysfunction in schizophrenia: evidence for compromised brain metabolism and oxidative stress. Mol Psychiatry. 2004 Jul. 9(7):684-97, 643. [QxMD MEDLINE Link].

36. Tkachev D, Mimmack ML, Ryan MM, Wayland M, Freeman T, Jones PB, et al. Oligodendrocyte dysfunction in schizophrenia and bipolar disorder. Lancet. 2003 Sep 6. 362(9386):798-805. [QxMD MEDLINE Link].

37. Adler CM, Holland SK, Schmithorst V, Wilke M, Weiss KL, Pan H, et al. Abnormal frontal white matter tracts in bipolar disorder: a diffusion tensor imaging study. Bipolar Disord. 2004 Jun. 6(3):197-203. [QxMD MEDLINE Link].

38. Adler CM, Adams J, DelBello MP, Holland SK, Schmithorst V, Levine A, et al. Evidence of white matter pathology in bipolar disorder adolescents experiencing their first episode of mania: a diffusion tensor imaging study. Am J Psychiatry. 2006 Feb. 163(2):322-4. [QxMD MEDLINE Link].

39. Bartzokis G. Neuroglialpharmacology: myelination as a shared mechanism of action of psychotropic treatments. Neuropharmacology. 2012 Jun. 62(7):2137-53. [QxMD MEDLINE Link]. [Full Text].

40. Chen G, Zeng WZ, Yuan PX, Huang LD, Jiang YM, Zhao ZH, et al. The mood-stabilizing agents lithium and valproate robustly increase the levels of the neuroprotective protein bcl-2 in the CNS. J Neurochem. 1999 Feb. 72(2):879-82. [QxMD MEDLINE Link].

41. Konradi C, Zimmerman EI, Yang CK, Lohmann KM, Gresch P, Pantazopoulos H, et al. Hippocampal interneurons in bipolar disorder. Arch Gen Psychiatry. 2011 Apr. 68(4):340-50. [QxMD MEDLINE Link]. [Full Text].

42. Mathew SJ, Manji HK, Charney DS. Novel drugs and therapeutic targets for severe mood disorders. Neuropsychopharmacology. Aug 2008;33(9):2300.

43. The HUGE project; research program on genes, environment, and health. multi-ethnic genome wide association study of bipolar disorder. Kaiser Permanente. [Full Text].

44. Axelson D, Goldstein B, Goldstein T, Monk K, Yu H, Hickey MB, et al. Diagnostic Precursors to Bipolar Disorder in Offspring of Parents With Bipolar Disorder: A Longitudinal Study. Am J Psychiatry. 2015 Mar 3. appiajp201414010035. [QxMD MEDLINE Link].

45. Frey BN, Andreazza AC, Houenou J, Jamain S, Goldstein BI, Frye MA, et al. Biomarkers in bipolar disorder: a positional paper from the International Society for Bipolar Disorders Biomarkers Task Force. Aust N Z J Psychiatry. 2013 Apr. 47(4):321-32. [QxMD MEDLINE Link].

46. The Columbia Bipolar Genetic Study. Bipolar disorder and genetics. Available at http://bipolar.hs.columbia.edu/disgenet.htm. Accessed: March 13, 2013.

47. Cardno AG, Rijsdijk FV, Sham PC, Murray RM, McGuffin P. A twin study of genetic relationships between psychotic symptoms. Am J Psychiatry. 2002 Apr. 159(4):539-45. [QxMD MEDLINE Link].

48. Berrettini WH. Are schizophrenic and bipolar disorders related? A review of family and molecular studies. Biol Psychiatry. 2000 Sep 15. 48(6):531-8. [QxMD MEDLINE Link].

49. Duffy A, Goodday S, Keown-Stoneman C, Grof P. The Emergent Course of Bipolar Disorder: Observations Over Two Decades From the Canadian High-Risk Offspring Cohort. Am J Psychiatry. 2018 Dec 11. appiajp201818040461. [QxMD MEDLINE Link].

50. Starzer MSK, Nordentoft M, Hjorthøj C. Rates and Predictors of Conversion to Schizophrenia or Bipolar Disorder Following Substance-Induced Psychosis. Am J Psychiatry. 2017 Nov 28. appiajp201717020223. [QxMD MEDLINE Link].

51. Hashimoto K, Sawa A, Iyo M. Increased levels of glutamate in brains from patients with mood disorders. Biol Psychiatry. 2007 Dec 1. 62(11):1310-6. [QxMD MEDLINE Link].

52. Houenou J, Frommberger J, Carde S, Glasbrenner M, Diener C, Leboyer M, et al. Neuroimaging-based markers of bipolar disorder: evidence from two meta-analyses. J Affect Disord. 2011 Aug. 132(3):344-55. [QxMD MEDLINE Link].

53. Tighe SK, Reading SA, Rivkin P, Caffo B, Schweizer B, Pearlson G, et al. Total white matter hyperintensity volume in bipolar disorder patients and their healthy relatives. Bipolar Disord. 2012 Dec. 14 (8):888-93. [QxMD MEDLINE Link].

54. Barnett JH, Huang J, Perlis RH, Young MM, Rosenbaum JF, Nierenberg AA, et al. Personality and bipolar disorder: dissecting state and trait associations between mood and personality. Psychol Med. 2011 Aug. 41(8):1593-604. [QxMD MEDLINE Link].

55. Chaudron LH, Pies RW. The relationship between postpartum psychosis and bipolar disorder: a review. J Clin Psychiatry. 2003 Nov. 64(11):1284-92. [QxMD MEDLINE Link].

56. Bauer M, Glenn T, Alda M, Aleksandrovich MA, Andreassen OA, et al. Solar insolation in springtime influences age of onset of bipolar I disorder. Acta Psychiatr Scand. 2017 Dec. 136 (6):571-582. [QxMD MEDLINE Link].

57. Aguglia A, Borsotti A, Maina G. Bipolar disorders: is there an influence of seasonality or photoperiod?. Rev Bras Psiquiatr. 2018 Jan-Mar. 40 (1):6-11. [QxMD MEDLINE Link].

58. Patel R, Reiss P, Shetty H, Broadbent M, Stewart R, McGuire P, et al. Do antidepressants increase the risk of mania and bipolar disorder in people with depression? A retrospective electronic case register cohort study. BMJ Open. 2015 Dec 14. 5 (12):e008341. [QxMD MEDLINE Link].

59. [Guideline] Hirschfeld RMA. Guideline Watch: Practice Guideline for the Treatment of Patients With Bipolar Disorder. Review and Synthesis of Available Evidence. Somatic Treatments of Acute Manic and Mixed Episodes. 2nd ed. Arlington, Va: American Psychiatric Association. [Full Text].

60. Calabrese JR. Overview of patient care issues and treatment in bipolar spectrum and bipolar II disorder. J Clin Psychiatry. 2008 Jun. 69(6):e18. [QxMD MEDLINE Link].

61. Merikangas KR, Jin R, He J-P, et al. Prevalence and correlates of bipolar spectrum disorder in the World Mental Health Survey Initiative. Arch Gen Psychiatry. 2011;68(3):241-251.

62. Yutzy SH, Woofter CR, Abbott CC, Melhem IM, Parish BS. The increasing frequency of mania and bipolar disorder: causes and potential negative impacts. J Nerv Ment Dis. 2012 May. 200(5):380-7. [QxMD MEDLINE Link]. [Full Text].

63. Diflorio A, Jones I. Is sex important? Gender differences in bipolar disorder. Int Rev Psychiatry. 2010. 22(5):437-52. [QxMD MEDLINE Link].

64. Hoang U, Stewart R, Goldacre MJ. Mortality after hospital discharge for people with schizophrenia or bipolar disorder: retrospective study of linked English hospital episode statistics, 1999-2006. BMJ. 2011 Sep 13. 343:d5422. [QxMD MEDLINE Link]. [Full Text].

65. Dogan S, Sabanciogullari S. The effects of patient education in lithium therapy on quality of life and compliance. Arch Psychiatr Nurs. 2003 Dec. 17(6):270-5. [QxMD MEDLINE Link].

66. National Institute of Mental Health. A story of bipolar disorder (manic-depressive illness). [Full Text].

67. Webb M. The years of silence are past: my father’s life with bipolar disorder. Am J Psychiatry. Dec 1 2003;160(12):2257.

68. Frye MA. Diagnostic dilemmas and clinical correlates of mixed states in bipolar disorder. J Clin Psychiatry. 2008 May. 69(5):e13. [QxMD MEDLINE Link].

69. American Psychiatric Association. Mixed features specifier. Available at http://www.dsm5.org/ProposedRevisions/Pages/proposedrevision.aspx?rid=483. Accessed: May 16, 2012.

70. Swann AC, Lafer B, Perugi G, Frye MA, Bauer M, Bahk WM, et al. Bipolar mixed states: an international society for bipolar disorders task force report of symptom structure, course of illness, and diagnosis. Am J Psychiatry. 2013 Jan 1. 170(1):31-42. [QxMD MEDLINE Link].

71. Bega S, Schaffer A, Goldstein B, Levitt A. Differentiating between Bipolar Disorder types I and II: results from the National Epidemiologic Survey on Alcohol and Related Conditions (NESARC). J Affect Disord. 2012 Apr. 138(1-2):46-53. [QxMD MEDLINE Link].

72. Frye MA, Nassan M, Jenkins GD, Kung S, Veldic M, Palmer BA, et al. Feasibility of investigating differential proteomic expression in depression: implications for biomarker development in mood disorders. Transl Psychiatry. 2015 Dec 8. 5:e689. [QxMD MEDLINE Link].

73. Krishna VN, Thunga R, Unnikrishnan B, Kanchan T, Bukelo MJ, Mehta RK, et al. Association between bipolar affective disorder and thyroid dysfunction. Asian J Psychiatr. 2013 Feb. 6(1):42-5. [QxMD MEDLINE Link].

74. Kenneson A, Funderburk JS, Maisto SA. Risk factors for secondary substance use disorders in people with childhood and adolescent-onset bipolar disorder: opportunities for prevention. Compr Psychiatry. 2013 Jul. 54(5):439-46. [QxMD MEDLINE Link].

75. Tohen M, Zarate CA Jr, Hennen J, Khalsa HM, Strakowski SM, Gebre-Medhin P, et al. The McLean-Harvard First-Episode Mania Study: prediction of recovery and first recurrence. Am J Psychiatry. 2003 Dec. 160(12):2099-107. [QxMD MEDLINE Link].

76. Berk M, Brnabic A, Dodd S, Kelin K, Tohen M, Malhi GS, et al. Does stage of illness impact treatment response in bipolar disorder? Empirical treatment data and their implication for the staging model and early intervention. Bipolar Disord. 2011 Feb. 13(1):87-98. [QxMD MEDLINE Link].

77. Goldstein TR, Ha W, Axelson DA, Goldstein BI, Liao F, Gill MK, et al. Predictors of prospectively examined suicide attempts among youth with bipolar disorder. Arch Gen Psychiatry. 2012 Nov. 69(11):1113-22. [QxMD MEDLINE Link]. [Full Text].

78. McIntyre RS, Soczynska JK, Beyer JL, Woldeyohannes HO, Law CW, Miranda A, et al. Medical comorbidity in bipolar disorder: re-prioritizing unmet needs. Curr Opin Psychiatry. 2007 Jul. 20(4):406-16. [QxMD MEDLINE Link].

79. Bradford DW, Kim MM, Braxton LE, Marx CE, Butterfield M, Elbogen EB. Access to medical care among persons with psychotic and major affective disorders. Psychiatr Serv. 2008 Aug. 59(8):847-52. [QxMD MEDLINE Link].

80. Woltmann E, Grogan-Kaylor A, Perron B, Georges H, Kilbourne AM, Bauer MS. Comparative effectiveness of collaborative chronic care models for mental health conditions across primary, specialty, and behavioral health care settings: systematic review and meta-analysis. Am J Psychiatry. 2012 Aug 1. 169(8):790-804. [QxMD MEDLINE Link].

81. Gutman DA, Nemeroff C. Medscape Education. Atypical antipsychotics in bipolar disorder. Available at http://www.medscape.org/viewarticle/554128. Accessed: June 27, 2007.

82. Bauer M, Ritter P, Grunze H, Pfennig A. Treatment options for acute depression in bipolar disorder. Bipolar Disord. 2012 May. 14 Suppl 2:37-50. [QxMD MEDLINE Link].

83. Post RM, Leverich GS, Altshuler LL, Frye MA, Suppes T, McElroy SL, et al. Relationship of prior antidepressant exposure to long-term prospective outcome in bipolar I disorder outpatients. J Clin Psychiatry. 2012 Jul. 73(7):924-30. [QxMD MEDLINE Link].

84. Kwentus J, Riesenberg RA, Marandi M, Manning RA, Allen MH, Fishman RS, et al. Rapid acute treatment of agitation in patients with bipolar I disorder: a multicenter, randomized, placebo-controlled clinical trial with inhaled loxapine. Bipolar Disord. 2012 Feb. 14(1):31-40. [QxMD MEDLINE Link].

85. Lesem MD, Tran-Johnson TK, Riesenberg RA, Feifel D, Allen MH, Fishman R, et al. Rapid acute treatment of agitation in individuals with schizophrenia: multicentre, randomised, placebo-controlled study of inhaled loxapine. Br J Psychiatry. 2011 Jan. 198(1):51-8. [QxMD MEDLINE Link].

86. Hou L, Heilbronner U, Degenhardt F, Adli M,. Genetic variants associated with response to lithium treatment in bipolar disorder: a genome-wide association study. Lancet. 2016 Jan 21. [QxMD MEDLINE Link].

87. Sajatovic M, Forester BP, Tsai J, Kroger H, Pikalov A, Cucchiaro J, et al. Efficacy of Lurasidone in Adults Aged 55 Years and Older With Bipolar Depression: Post Hoc Analysis of 2 Double-Blind, Placebo-Controlled Studies. J Clin Psychiatry. 2016 Oct. 77 (10):e1324-e1331. [QxMD MEDLINE Link]. [Full Text].

88. Bauer M, Alda M, Priller J, Young LT. Implications of the neuroprotective effects of lithium for the treatment of bipolar and neurodegenerative disorders. Pharmacopsychiatry. 2003 Nov. 36 Suppl 3:S250-4. [QxMD MEDLINE Link].

89. McKnight RF, Adida M, Budge K, Stockton S, Goodwin GM, Geddes JR. Lithium toxicity profile: a systematic review and meta-analysis. Lancet. 2012 Feb 25. 379(9817):721-8. [QxMD MEDLINE Link].

90. Ansari A, Osser DN. The psychopharmacology algorithm project at the Harvard South Shore Program: an update on bipolar depression. Harv Rev Psychiatry. 2010 Jan-Feb. 18(1):36-55. [QxMD MEDLINE Link].

91. Diazgranados N, Ibrahim L, Brutsche NE, Newberg A, Kronstein P, Khalife S, et al. A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression. Arch Gen Psychiatry. 2010 Aug. 67(8):793-802. [QxMD MEDLINE Link]. [Full Text].

92. Sidor MM, Macqueen GM. Antidepressants for the acute treatment of bipolar depression: a systematic review and meta-analysis. J Clin Psychiatry. 2011 Feb. 72(2):156-67. [QxMD MEDLINE Link].

93. Geddes JR, Goodwin GM, Rendell J, Azorin JM, Cipriani A, Ostacher MJ, et al. Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet. 2010 Jan 30. 375(9712):385-95. [QxMD MEDLINE Link].

94. Kessing LV, Hellmund G, Geddes JR, Goodwin GM, Andersen PK. Valproate v. lithium in the treatment of bipolar disorder in clinical practice: observational nationwide register-based cohort study. Br J Psychiatry. 2011 Jul. 199(1):57-63. [QxMD MEDLINE Link].

95. Swartz HA, Thase ME. Pharmacotherapy for the treatment of acute bipolar II depression: current evidence. J Clin Psychiatry. 2011 Mar. 72(3):356-66. [QxMD MEDLINE Link].

96. Smith LA, Cornelius V, Warnock A, Bell A, Young AH. Effectiveness of mood stabilizers and antipsychotics in the maintenance phase of bipolar disorder: a systematic review of randomized controlled trials. Bipolar Disord. 2007 Jun. 9(4):394-412. [QxMD MEDLINE Link].

97. Popovic D, Reinares M, Goikolea JM, Bonnin CM, Gonzalez-Pinto A, Vieta E. Polarity index of pharmacological agents used for maintenance treatment of bipolar disorder. Eur Neuropsychopharmacol. 2012 May. 22(5):339-46. [QxMD MEDLINE Link].

98. Pappadopulos E, Newcomer JW, Kolluri S. Changes in weight, plasma lipids, and glucose in adults treated with ziprasidone: a comprehensive analysis of pfizer-initiated clinical trials. J Clin Psychiatry. 2012 Jun. 73(6):e742-8. [QxMD MEDLINE Link].

99. Calabrese JR, Sanchez R, Jin N, Amatniek J, Cox K, Johnson B, et al. Efficacy and Safety of Aripiprazole Once-Monthly in the Maintenance Treatment of Bipolar I Disorder: A Double-Blind, Placebo-Controlled, 52-Week Randomized Withdrawal Study. J Clin Psychiatry. 2017 Mar. 78 (3):324-331. [QxMD MEDLINE Link]. [Full Text].

100. Cipriani A, Barbui C, Salanti G, Rendell J, Brown R, Stockton S, et al. Comparative efficacy and acceptability of antimanic drugs in acute mania: a multiple-treatments meta-analysis. Lancet. 2011 Oct 8. 378(9799):1306-15. [QxMD MEDLINE Link].

101. Tohen M, Goldberg JF, Gonzalez-Pinto Arrillaga AM, Azorin JM, Vieta E, Hardy-Bayle MC, et al. A 12-week, double-blind comparison of olanzapine vs haloperidol in the treatment of acute mania. Arch Gen Psychiatry. 2003 Dec. 60(12):1218-26. [QxMD MEDLINE Link].

102. Tohen M, Baker RW, Altshuler LL, Zarate CA, Suppes T, Ketter TA, et al. Olanzapine versus divalproex in the treatment of acute mania. Am J Psychiatry. 2002 Jun. 159(6):1011-7. [QxMD MEDLINE Link].

103. Tohen M, Chengappa KN, Suppes T, Zarate CA Jr, Calabrese JR, Bowden CL, et al. Efficacy of olanzapine in combination with valproate or lithium in the treatment of mania in patients partially nonresponsive to valproate or lithium monotherapy. Arch Gen Psychiatry. 2002 Jan. 59(1):62-9. [QxMD MEDLINE Link].

104. Sachs GS, Grossman F, Ghaemi SN, Okamoto A, Bowden CL. Combination of a mood stabilizer with risperidone or haloperidol for treatment of acute mania: a double-blind, placebo-controlled comparison of efficacy and safety. Am J Psychiatry. 2002 Jul. 159(7):1146-54. [QxMD MEDLINE Link]. [Full Text].

105. Yatham LN, Grossman F, Augustyns I, Vieta E, Ravindran A. Mood stabilisers plus risperidone or placebo in the treatment of acute mania. International, double-blind, randomised controlled trial. Br J Psychiatry. 2003 Feb. 182:141-7. [QxMD MEDLINE Link].

106. [Guideline] Hirschfeld RMA, Bowden CL, Gitlin MJ, et al, for the Work Group on Bipolar Disorder. Practice guideline for the treatment of patients with bipolar disorder, second edition. American Psychiatric Association. Available at http://www.psychiatryonline.com/pracGuide/PracticePDFs/Bipolar2e_Inactivated_04-16-09.pdf. Accessed: April 14, 2011.

107. Hamrin V, Iennaco JD. Psychopharmacology of pediatric bipolar disorder. Expert Rev Neurother. 2010 Jul. 10(7):1053-88. [QxMD MEDLINE Link].

108. Geller B, Luby JL, Joshi P, Wagner KD, Emslie G, Walkup JT, et al. A randomized controlled trial of risperidone, lithium, or divalproex sodium for initial treatment of bipolar I disorder, manic or mixed phase, in children and adolescents. Arch Gen Psychiatry. 2012 May. 69(5):515-28. [QxMD MEDLINE Link]. [Full Text].

109. Jeffrey S. FDA warns of aseptic meningitis risk with lamotrigine. FDA warns of aseptic meningitis risk with lamotrigine. Available at http://www.medscape.com/viewarticle/726845. Accessed: August 12, 2010.

110. Brooks JO 3rd, Goldberg JF, Ketter TA, et al. Safety and tolerability associated with second-generation antipsychotic polytherapy in bipolar disorder: findings from the Systematic Treatment Enhancement Program for Bipolar Disorder. J Clin Psychiatry. Feb 2011;72(2):240-7. [QxMD MEDLINE Link].

111. Mukherjee S, Sackeim HA, Schnur DB. Electroconvulsive therapy of acute manic episodes: a review of 50 years' experience. Am J Psychiatry. 1994 Feb. 151(2):169-76. [QxMD MEDLINE Link].

112. Sarris J, Mischoulon D, Schweiter I. Omega-3 for bipolar disorder: meta-analyses of use in mania and bipolar depression. J Clin Psychiatry. 2011;Online ahead of print.

113. Hong CJ, Huo SJ, Yen FC, Tung CL, Pan GM, Tsai SJ. Association study of a brain-derived neurotrophic-factor genetic polymorphism and mood disorders, age of onset and suicidal behavior. Neuropsychobiology. 2003. 48(4):186-9. [QxMD MEDLINE Link].

114. Ilgen MA, Bohnert AS, Ignacio RV, McCarthy JF, Valenstein MM, Kim HM, et al. Psychiatric diagnoses and risk of suicide in veterans. Arch Gen Psychiatry. 2010 Nov. 67(11):1152-8. [QxMD MEDLINE Link].

115. Bellivier F, Yon L, Luquiens A, Azorin JM, Bertsch J, Gerard S, et al. Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). Bipolar Disord. 2011 Jun. 13(4):377-86. [QxMD MEDLINE Link].

116. Fazel S, Lichtenstein P, Grann M, Goodwin GM, Långström N. Bipolar disorder and violent crime: new evidence from population-based longitudinal studies and systematic review. Arch Gen Psychiatry. 2010 Sep. 67(9):931-8. [QxMD MEDLINE Link].

117. Saarni SI, Viertiö S, Perälä J, Koskinen S, Lönnqvist J, Suvisaari J. Quality of life of people with schizophrenia, bipolar disorder and other psychotic disorders. Br J Psychiatry. 2010 Nov. 197(5):386-94. [QxMD MEDLINE Link].

118. Fiedorowicz JG, Endicott J, Leon AC, Solomon DA, Keller MB, Coryell WH. Subthreshold hypomanic symptoms in progression from unipolar major depression to bipolar disorder. Am J Psychiatry. 2011 Jan. 168(1):40-8. [QxMD MEDLINE Link]. [Full Text].

119. Leibenluft E. Severe mood dysregulation, irritability, and the diagnostic boundaries of bipolar disorder in youths. Am J Psychiatry. 2011 Feb. 168(2):129-42. [QxMD MEDLINE Link]. [Full Text].

120. McCrea RL1, Nazareth I1, Evans SJ2, Osborn DP3, Pinfold V4, Cowen PJ5, et al. Lithium prescribing during pregnancy: a UK primary care database study. PLoS One. March 20, 2015. 10:[QxMD MEDLINE Link]. [Full Text].

121. Dubovsky S. The real risk for suicide in mental disorders. Medscape News Today. Available at http://www.medscape.com/viewarticle/754885. Accessed: April 26, 2012.

122. Bellivier F, Yon L, Luquiens A, Azorin JM, Bertsch J, Gerard S, et al. Suicidal attempts in bipolar disorder: results from an observational study (EMBLEM). Bipolar Disord. 2011 Jun. 13(4):377-86. [QxMD MEDLINE Link].

123. Volavka J. Violence in schizophrenia and bipolar disorder. Psychiatr Danub. 2013 Mar. 25(1):24-33. [QxMD MEDLINE Link].

124. Fagiolini A. Medical monitoring in patients with bipolar disorder: a review of data. J Clin Psychiatry. 2008 Jun. 69(6):e16. [QxMD MEDLINE Link].

125. Keck PE Jr. Evaluating treatment decisions in bipolar depression. Available at http://www.medscape.com/viewprogram/2571. Accessed: Dec 30, 2003.

126. Marcotte D. Use of topiramate, a new anti-epileptic as a mood stabilizer. J Affect Disord. 1998 Sep. 50(2-3):245-51. [QxMD MEDLINE Link].

127. American Psychiatric Association. Bipolar and related disorders. Available at http://www.dsm5.org/ProposedRevision/Pages/BipolarandRelatedDisorders.aspx. Accessed: May 16, 2012.

128. American Psychiatric Association. DSM-5: the future of psychiatric diagnosis. Available at http://www.dsm5.org/Pages/Default.aspx. Accessed: May 16, 2012.

129. Angst J, Azorin JM, Bowden CL, Perugi G, Vieta E, Gamma A, et al. Prevalence and characteristics of undiagnosed bipolar disorders in patients with a major depressive episode: the BRIDGE study. Arch Gen Psychiatry. 2011 Aug. 68(8):791-8. [QxMD MEDLINE Link].

130. Angst J, Gamma A, Bowden CL, Azorin JM, Perugi G, Vieta E, et al. Diagnostic criteria for bipolarity based on an international sample of 5,635 patients with DSM-IV major depressive episodes. Eur Arch Psychiatry Clin Neurosci. 2012 Feb. 262(1):3-11. [QxMD MEDLINE Link].

131. Lepping P, Menkes DB. Abuse of dosulepin to induce mania. Addiction. 2007 Jul. 102(7):1166-7. [QxMD MEDLINE Link].

132. Lewitzka, U. and Bauer, M. What Role Does (Should) Lithium Play in Suicide Treatment/Prevention?. Psychiatric Times. Available at http://www.psychiatrictimes.com/special-reports/what-role-does-should-lithium-play-in-suicide-treatment-prevention. Accessed: January 16, 2015.

133. Schöttle D, Huber CG, Bock T, Meyer TD. Psychotherapy for bipolar disorder: a review of the most recent studies. Curr Opin Psychiatry. 2011 Nov. 24(6):549-55. [QxMD MEDLINE Link].

134. Wolkenstein L, Bruchmüller K, Schmid P, Meyer TD. Misdiagnosing bipolar disorder--do clinicians show heuristic biases?. J Affect Disord. 2011 May. 130(3):405-12. [QxMD MEDLINE Link].

135. Song J, Sjölander A, Joas E, Bergen SE, Runeson B, Larsson H, et al. Suicidal Behavior During Lithium and Valproate Treatment: A Within-Individual 8-Year Prospective Study of 50,000 Patients With Bipolar Disorder. Am J Psychiatry. 2017 Aug 1. 174 (8):795-802. [QxMD MEDLINE Link].

136. Calabrese JR, Durgam S, Satlin A, Vanover KE, Davis RE, Chen R, et al. Efficacy and Safety of Lumateperone for Major Depressive Episodes Associated With Bipolar I or Bipolar II Disorder: A Phase 3 Randomized Placebo-Controlled Trial. Am J Psychiatry. 2021 Dec. 178 (12):1098-1106. [QxMD MEDLINE Link].

Stephen Soreff, MD President of Education Initiatives, Nottingham, NH; Faculty, Boston University, Boston, MA and Daniel Webster College, Nashua, NH

Stephen Soreff, MD is a member of the following medical societies: ACMHA: The College for Behavioral Health Leadership

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Received salary from Medscape for employment. for: Medscape.

Glen L Xiong, MD Associate Clinical Professor, Department of Psychiatry and Behavioral Sciences, Department of Internal Medicine, University of California, Davis, School of Medicine; Medical Director, Sacramento County Mental Health Treatment Center

Glen L Xiong, MD is a member of the following medical societies: AMDA - The Society for Post-Acute and Long-Term Care Medicine, American College of Physicians, American Psychiatric Association, Central California Psychiatric Society

Disclosure: Serve(d) as a director, officer, partner, employee, advisor, consultant or trustee for: SafelyYou, Blue Cross Blue Shield<br/>book co-editor for: Wolter Kluwer, American Psychiatric Publishing Inc.

Lynne Alison McInnes, MD, MS Associate Clinical Professor of Psychiatry, University of California, San Francisco, School of Medicine

Lynne Alison McInnes, MD, MS is a member of the following medical societies: Alpha Omega Alpha, American Psychiatric Association, American Society of Human Genetics

Disclosure: Nothing to disclose.

Francisco Talavera, PharmD, PhD Adjunct Assistant Professor, University of Nebraska Medical Center College of Pharmacy; Editor-in-Chief, Medscape Drug Reference

Disclosure: Medscape Salary Employment

• Print this section
• Print the entire contents of
• Print the entire contents of article